Alzheimer’s Disease and Lewy Body Co‐Pathology Presenting with Corticobasal Syndrome
AD and LBD commonly occur together, but the frequency of AD and LBD as a cause of CBS is unknown. Here, we add to the literature of co-pathology in CBS and consider that early age and rapid progression could suggest dual pathology and potential synergistic effects. CSF testing limited to AD biomarkers will miss this dual pathology. Thus, CSF α-synuclein seeding amplification may help identify patients with dual AD-LBD pathology and assist prognostication.
Authors
- Michael Zeineh (ORCID: https://orcid.org/0000-0002-6940-9096)
- Jeffrey Nirschl (ORCID: https://orcid.org/0000-0001-6857-341X)
- Claire Delpirou Nouh (ORCID: https://orcid.org/0000-0002-8146-9702)
- Simon Tan (ORCID: https://orcid.org/0009-0008-5567-5108)
- Sharon J. Sha (ORCID: https://orcid.org/0000-0002-3666-1463)
- Kristen Vallejo (ORCID: https://orcid.org/0009-0005-1418-7931)
Institutions
- Stanford University (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/alz.088634
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00